Sign inJoin waitlistJoin the waitlist

Noah Merin

Assistant Professor, Medicine · Cedars-Sinai Medical Center

Credentials: · · ·

History

Cedars-Sinai Medical Center
Present

Hematology and Medical Oncology
Keck Medicine of USC
2011–2014
Internal Medicine
University of California-Davis
2008–2011
University of California, Davis, School of Medicine
2004–2008

Research

Gaze behavior and affect at 6 months: predicting clinical outcomes and language development in typically developing infants and infants at risk for autism
Developmental Science · 2009 · 223 citations
Visual Fixation Patterns during Reciprocal Social Interaction Distinguish a Subgroup of 6-Month-Old Infants At-Risk for Autism from Comparison Infants
Journal of Autism and Developmental Disorders · 2007 · First of 4 authors · 146 citations
SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus
Communications Biology · 2021 · 93 citations

Akil Merchant
15 papers
Karen Reckamp
9 papers
Robert Vescio
8 papers
Ronald Paquette
8 papers
Justin Darrah
7 papers · 1 as a resident
Dermot McGovern
6 papers
Jonathan Braun
6 papers
Gil Melmed
5 papers
Inderjit Mehmi
5 papers
Jun Gong
5 papers
Omid Hamid
5 papers
Susan Cheng
5 papers

Grants

Diversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2
National Cancer Institute · U54
Project lead · $1.1M · Cedars-Sinai Medical Center
2020–2025

Clinical trials

Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure
Principal investigator · Terminated · Early phase 1
Noah Merin
2020
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Principal investigator · Completed · Phase 1
Cedars-Sinai Medical Center
2020–2024
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Principal investigator · Completed · Phase 1
Noah Merin
2018–2024
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029